Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02139761
Other study ID # HP-00059193
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date September 2014
Est. completion date June 2016

Study information

Verified date October 2019
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cocaine continues to be one of the most widely used substances of abuse around the world. In the US, an estimated 1.4 million individuals (0.5%) > 12 years were current (past month) cocaine users in 2011. Currently, no FDA-approved pharmacologic treatments are available for cocaine addiction; thus, this remains a serious public health problem without an effective pharmacological treatment. A promising lead towards an effective treatment comes from a recent finding that pretreatment with oral l-tetrahydropalmitine (l-THP) in rats attenuated the cocaine seeking associated with a cocaine challenge, while having no motor effects. This finding stimulated our group to test the pharmacokinetics and safety of l-THP in a phase I study of people with cocaine use. Preliminary findings show l-THP is safe and well tolerated in cocaine users, with no adverse interactions with cocaine.

This study will test the efficacy and safety of l-THP for abstinence in those with cocaine addiction in a phase II pilot study (N=24). Secondarily, we will examine the effects of these medications on craving.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- men or non-pregnant/non-nursing women between the ages of 18 and 50 years

- meeting criteria for DSM-5 cocaine use disorder

- self-reported cocaine use (intranasal, IV or smoked) averaging at least weekly for the prior six months positive urine drug test for cocaine in the prior month

- HIV seronegative

- EKG without clinically significant abnormality

- normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and resting heart rate (60-90 bpm)

- ability to adhere to the study restrictions and examination schedule

- women with reproductive potential must agree to the use of one of the following birth control methods (oral contraceptives, condom with spermicide, diaphragm, or intrauterine device) during the study and for 2 weeks after last medication dose.

Exclusion Criteria:

- participation in any investigational drug trial or clinical drug trial within 45 days before study entry

- history of clinically significant adverse reaction or hypersensitivity to cocaine or l-THP

- inability to communicate or co-operate with the investigators

- currently taking any prescribed psychoactive medication, e.g., anti- depressant, anti-psychotic, or mood stabilizer

- current clinically significant medical problem that might interfere with safe study participation. This includes pheochromocytoma, untreated hyperthyroidism, dehydration, fever, coronary artery disease, uncorrected congenital heart defect, seizures, electrolyte imbalance, uncontrolled diabetes mellitus, porphyria variegate, superventricular tachycardia, atrial fibrillation, cardiomyopathy, or uncontrolled hypertension.

- current Axis I Major Depression, Schizophrenia, or Bipolar Disorder.

- score below 10/12 on the Evaluation to Sign Consent (ESC)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
l-tetrahydropalmatine (l-THP)
Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
Placebo
Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.

Locations

Country Name City State
United States Maryland Psychiatric Research Center Catonsville Maryland

Sponsors (2)

Lead Sponsor Collaborator
University of Maryland, Baltimore National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary We will assess abstinence to cocaine as the outcome We will measure cocaine and its metabolite by urine drug test to assess for abstinence. 8 Weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05974202 - rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder Phase 2
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Active, not recruiting NCT05809453 - Intranasal Cocaine and Temperature Regulation During Exercise Phase 1/Phase 2
Completed NCT01851473 - Interactions Between Intravenous Cocaine and Acetazolamide or Quinine Phase 1
Completed NCT04061941 - Change in Cognitive Function in Stimulant Users
Completed NCT01631383 - Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use Phase 1
Withdrawn NCT01222806 - Pilot Study of Repetitive Transcranial Magnetic Stimulation in Cocaine Craving Phase 1
Recruiting NCT06177860 - Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use
Completed NCT04418076 - Project SMART Automated Pillbox Study N/A
Recruiting NCT05766631 - Treating Polysubstance Use Using a Novel Digital Technology Phase 3
Enrolling by invitation NCT05704764 - Using the Ending Self-Stigma Intervention to Reduce Internalized Stigma Among People Living With HIV Who Use Substances N/A
Not yet recruiting NCT06045793 - Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) Phase 2
Not yet recruiting NCT05824221 - Effect of rTMS on Neurotrophines Levels in CUD N/A